Zobrazeno 1 - 10
of 422
pro vyhledávání: '"Betts CJ"'
Autor:
Gardner J; Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, United Kingdom., Ogese M; Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, United Kingdom., Betts CJ; Clinical Pharmacology and Safety Sciences, R&D Biopharmaceuticals, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Pirmohamed M; Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, United Kingdom., Naisbitt DJ; Department of Molecular and Clinical Pharmacology, University of Liverpool, Sherrington Building, Ashton Street, Liverpool L69 3GE, United Kingdom.
Publikováno v:
Chemical research in toxicology [Chem Res Toxicol] 2022 Feb 21; Vol. 35 (2), pp. 199-202. Date of Electronic Publication: 2022 Feb 02.
Autor:
Liu G; Respiratory and Immunology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Särén L; Animal Sciences and Technologies, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Douglasson H; Bioscience Cough and in Vivo, Early Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Zhou XH; Patient Safety, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Åberg PM; Respiratory and Immunology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Ollerstam A; Respiratory and Immunology Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Betts CJ; Functional and Mechanistic Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, UK. Catherine.Betts@astrazeneca.com., Balogh Sivars K; Clinical Testing, Global Procurement, Operations, AstraZeneca, Gothenburg, Sweden. Kinga.Balogh-Sivars@astrazeneca.com.
Publikováno v:
Archives of toxicology [Arch Toxicol] 2021 Aug; Vol. 95 (8), pp. 2871-2877. Date of Electronic Publication: 2021 Jun 30.
Autor:
Afshar, Hanyeh1 (AUTHOR), Simpson, Alexandra1 (AUTHOR), Taylor, Elena1 (AUTHOR), Miles, Ashley1 (AUTHOR), Chen, Herbert R.1 (AUTHOR), Newsome, Scott D.1 (AUTHOR) snewsom2@jhmi.edu
Publikováno v:
Orphanet Journal of Rare Diseases. 9/27/2024, Vol. 19 Issue 1, p1-7. 7p.
Autor:
Callender LA; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.; Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical, Cambridge, United Kingdom., Curran M; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.; Department of Surgery, University of Cambridge, NIHR Cambridge Biomedical, Cambridge, United Kingdom., Bates SM; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.; Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom., Mairesse M; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Weigandt J; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom., Betts CJ; Immunotoxicology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge, United Kingdom.
Publikováno v:
Frontiers in immunology [Front Immunol] 2020 Aug 11; Vol. 11, pp. 1991. Date of Electronic Publication: 2020 Aug 11 (Print Publication: 2020).
Autor:
Curran M; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Campus, Cambridge, United Kingdom., Mairesse M; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Matas-Céspedes A; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.; Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Campus, Cambridge, United Kingdom., Bareham B; Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Campus, Cambridge, United Kingdom., Pellegrini G; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Liaunardy A; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Powell E; Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Campus, Cambridge, United Kingdom., Sargeant R; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Cuomo E; Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Stebbings R; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Betts CJ; Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom., Saeb-Parsy K; Department of Surgery, University of Cambridge and NIHR Cambridge Biomedical Campus, Cambridge, United Kingdom.
Publikováno v:
Toxicologic pathology [Toxicol Pathol] 2020 Feb; Vol. 48 (2), pp. 302-316. Date of Electronic Publication: 2019 Dec 18.
Autor:
Hardwick RN; Translational Safety Sciences, Theravance Biopharma, US, Inc., South San Francisco, CA, USA. rhardwick@theravance.com., Betts CJ; Pathology Sciences, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca, Cambridge, UK., Whritenour J; Pfizer, Inc., Drug Safety Research and Development, Eastern Point Rd, Groton, CT 06340, USA., Sura R; Preclinical Safety, Abbvie Inc., North Chicago, IL, USA., Thamsen M; Pharmacology, Theravance Biopharma, US, Inc., South San Francisco, CA, USA., Kaufman EH; Biology, Theravance Biopharma, US, Inc., South San Francisco, CA, USA., Fabre K; MPS Center of Excellence, Drug Safety & Metabolism, IMED Biotech Unit, AstraZeneca, Waltham, MA, USA.
Publikováno v:
Lab on a chip [Lab Chip] 2020 Jan 21; Vol. 20 (2), pp. 199-214. Date of Electronic Publication: 2019 Oct 10.
Autor:
Adedeji AO; 1 Department of Safety Assessment, Genentech, A Member of the Roche Group, South San Francisco, CA, USA., Pourmohamad T; 1 Department of Safety Assessment, Genentech, A Member of the Roche Group, South San Francisco, CA, USA., Chen Y; 2 Janssen Research & Development, LLC, San Diego, CA, USA., Burkey J; 3 Critical Path Institute, Tucson, AZ, USA., Betts CJ; 4 IMED Biotech Unit, AstraZeneca, United Kingdom., Bickerton SJ; 4 IMED Biotech Unit, AstraZeneca, United Kingdom., Sonee M; 2 Janssen Research & Development, LLC, San Diego, CA, USA., McDuffie JE; 2 Janssen Research & Development, LLC, San Diego, CA, USA.
Publikováno v:
International journal of toxicology [Int J Toxicol] 2019 Jan/Feb; Vol. 38 (1), pp. 12-22. Date of Electronic Publication: 2019 Jan 23.
Autor:
Balogh Sivars K; Discovery Safety, Drug Safety and Metabolism., Sivars U; Respiratory, Inflammation and Autoimmunity., Hornberg E; Respiratory, Inflammation and Autoimmunity., Zhang H; Pathology, Drug Safety and Metabolism., Brändén L; Respiratory, Inflammation and Autoimmunity., Bonfante R; Epithelix Sàrl, CH-1228 Geneva, Switzerland., Huang S; Epithelix Sàrl, CH-1228 Geneva, Switzerland., Constant S; Epithelix Sàrl, CH-1228 Geneva, Switzerland., Robinson I; Regulatory Safety, Drug Safety and Metabolism., Betts CJ; Pathology, Drug Safety and Metabolism., Åberg PM; Regulatory Safety, Drug Safety and Metabolism.
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2018 Mar 01; Vol. 162 (1), pp. 301-308.
Autor:
Silva Junior, Danyllo do Nascimento1,2 (NURSE), de Sousa Mata, Ádala Nayana2,3,4 (NURSE), Silva de Medeiros, Gidyenne Christine Bandeira1,2,5 (NURSE), Marques, Marilane Vilela1,2 (NURSE), dos Santos, Thais Teixeira1,2 (NURSE), de Sousa Monteiro, Maria Eduarda2,4 (NURSE), Costa, Gabriela Góis2,4 (NURSE), d´Orsi, Eleonora6 (AUTHOR), Parra, Eva Vegue7 (AUTHOR), Piuvezam, Grasiela1,2,8 (NURSE) gpiuvezam@yahoo.com.br
Publikováno v:
PLoS ONE. 4/18/2024, Vol. 19 Issue 4, p1-9. 9p.
Autor:
Ogese MO; Pathology Sciences, Drug Safety and Metabolism, AstraZeneca R&D, Cambridge Science Park, Cambridge CB4 0WG, UK., Faulkner L; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., Jenkins RE; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., French NS; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., Copple IM; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., Antoine DJ; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., Elmasry M; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK.; North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Liverpool L9 7AL, UK., Malik H; North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Liverpool L9 7AL, UK., Goldring CE; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., Park BK; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK., Betts CJ; Pathology Sciences, Drug Safety and Metabolism, AstraZeneca R&D, Cambridge Science Park, Cambridge CB4 0WG, UK., Naisbitt DJ; Department of Molecular and Clinical Pharmacology, MRC Centre for Drug Safety Science, University of Liverpool, Liverpool L69 3GE, UK.
Publikováno v:
Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2017 Jul 01; Vol. 158 (1), pp. 76-89.